



23rd March 2025:

Pre Event Day: Cancer Vaccines & Personalised Cancer Therapies

- Inverse vaccine strategies
- Non-antigen-specific immunomodulatory vaccines & SLIT (Sublingual immunotherapy)
- Preventive prophylactic vaccines
 - HPV
 - Hepatitis B
- Therapeutic vaccines
 - Sipuleucel- T for prostate cancer
- Vaccines for melanoma, lung cancer
- Personalised vs universal vaccine approaches
- Neoantigen-based vaccines

24th March 2025:

Day 1 Track 8: Discovery & Development Of Therapies For Cancer & Autoimmune Diseases

- Cell-based therapeutics: CAR-T, CAR-NK cell therapies
- Challenges in advancing IO therapies
- Personalized cell therapy & cancer neoepitopes
- Advanced immune regulation strategies
- Gene therapies targeting immune system responses
- Anti-T cell therapies: CD3, CD19, CD20, and others
- T-cell or APC-specific therapies
- mRNA-based CAR-T therapies
- Cytokine therapies
- Tolerization immunotherapy
- Inverse vaccine strategies
- Tolerogenic dendritic cell (DC) immunotherapy
- Non-antigen-specific immunomodulatory vaccines & SLIT (Sublingual immunotherapy)
- Clinical development & trial strategies for immunotherapies

Day 1 Track 9: Clinical Insights In Immuno- Oncology: Biomarkers, Pharmacokinetics & Safety Monitoring

- Biomarker strategies in the era of PD-1 checkpoint combination therapies
- Development & delivery of personalised immunotherapy
- New biomarker technologies in the prediction of response
- Technologies for biomarker development of patient populations
- Patient selection & stratification for immuno-oncology

Day 1 Track 10: NextGen Targets & Therapeutic Strategies: Identification, Validation, Biomarkers & Emerging Platforms

- Discovery of best-in-class therapeutic antibodies in IO
- Biomarker discovery and validation for target selection and patient stratification
- Emerging target identification and validation strategies, methods
- Technological approaches:
 - High-throughput screening
 - Computational biology
 - Genomic sequencing
 - CRISPR
- Novel identification strategies
- Exploring new immune checkpoint targets
 - TIGIT
 - LAG-3
 - VISTA
- Recent progress: immune checkpoint inhibitors
- Targeting the PD-1 pathway and finding alternative therapeutic targets

25th March 2025:

Day 2 Track 8: Optimising Clinical Development: Efficacy, Safety & Combination Strategies

- Innovations in imaging technologies (e.g., PET, MRI, and advanced CT scans) for monitoring tumour dynamics and immunotherapy response in real-time
- Non-invasive imaging to assess immune cell infiltration and efficacy of combination therapies
- Use of patient-derived tumor organoids and 3D culture systems to simulate tumor microenvironments for drug screening and combination therapy testing
- In silico modeling and high-throughput screening to identify the most promising combinations of immune checkpoint inhibitors, cytokines, and other immunotherapies
- Liquid biopsies & ctDNA:
 - Early detection techniques
 - Does sensitivity matter?
 - ctDNA kinetics & endpoints

Day 2 Track 9: Multi-Omics Approaches In Immunotherapies

- Multi-omics technologies in IO
- Utilisation of spatial technologies in immuno-oncology
- Genetic analysis technologies for immuno-oncology research
- NextGen & single cell sequencing
- Digital pathology for immuno-oncology
- Microarrays

Day 2 Track 10: Translational Models in Immuno-Oncology: In Vitro & In Vivo Approaches

- Maximising translatability through effective in vitro and in vivo models
- Humanised & 3D mouse models
- Choosing the right preclinical models for assessing safety and efficacy
- Technologies to transition from animal testing
- Non-clinical approaches for predicting single agent vs combination value
- The role of the tumour microenvironment in ensuring clinical success

2025 Speakers Included:



Annelise Vuidepot
Immunocore



Daniel Larocque
Sanofi Vaccines



Livija Deban
Prokarium



Helene Kaplon
Servier



Hester van Zeeburg
Mendus AG



Rita Martelolo
Merck KGaA

Benefits Of Attending

- ✓ **Hear from and meet with key innovators in immunotherapy & immuno-oncology.** 2025 attendees included: Senior Director, AstraZeneca; Director, Merck KGaA and Vice President, Translational Biology, Crescendo Biologics
- ✓ **New to 2026! Gain invaluable insights into advancing the discovery & development of immunotherapies to treat cancer & autoimmune diseases.** Aligned with current industry trends, the 2026 programme will provide exclusive insights into cell-based therapeutics approaches, cytokine therapies and tolerization immunotherapies
- ✓ **Be at the forefront of nextgen targets & novel therapeutic strategies innovations.** Hear about advancements in the discovery of best-in-class therapeutic antibodies, biomarker discovery & validation and the latest technological approaches
- ✓ **New to 2026! Unlock the power of multi-omics approaches in immunotherapy.** Thought-leaders will be discussing the utilization of spatial technologies in immunotherapy research, single cell sequencing & digital pathology for immune-oncology
- ✓ **Take a deep dive into using translational models in immuno-oncology.** Gain invaluable insights into *in vivo* and *in vitro* approaches, humanized & 3D mouse models and the role of the tumour microenvironment in ensuring clinical success
- ✓ **Part of NextGen Biomed, the event also features the Proteins & Antibodies, Peptides & Oligonucleotides, and Vaccines programmes under one roof** – creating a unique opportunity to connect across modalities, discover cross-cutting innovations, and accelerate the development of next-generation biomedicines to market

Meet Senior Decision Makers

Over 1000 VPs, Directors & Professors from leading pharmaceutical organisations, biotech companies and academic institutions will attend NextGen Biomed. Delegate job titles include:

Immuno-Oncology
Translational Medicine
Translational Immunology

Immunotherapy
Clinical Development
Pre-Clinical Development

Cellular Therapy
T Cell Immunotherapy
Car-T Immunotherapy

Combination Therapies
Antibody Therapies
Cancer Immunity

Translational Tools
Target Validation
Lead Identification

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Immunotherapy Antibodies
Immunotherapy Platforms
Cancer Vaccines

Animal Models
Checkpoint Marker Detection
Immune Cell Characterisation

Checkpoint Inhibitors
Engineered Oncolytic Viruses
Microbiome Analysis

Immunotherapy Adjuvants
mABs
Microbiome Modulation

Humanized Mouse
Target Validation
Lead Identification

Immunotherapy & Immuno-Oncology 2026 Speakers:

- John Bridgeman, Chief Scientific Officer, Immuno Key
- Lilly Wollman, Chief Executive Officer, Synteny
- Annelise Vuidepot, Chief Technology Officer, Research & UK Site Lead, Immunocore
- Sonia Macia, Chief Medical Officer, Aromics Therapeutics
- James Legg, Chief Scientific Officer, Cytospire Therapeutics
- Livija Deban, Chief Scientific Officer, Prokarium
- Robert Wilkinson, Vice President, Research, Immunocore
- Stefan Zielonka, Global Head of Antibody Discovery & Protein Engineering, Merck Healthcare KGaA
- Miguel Gaspar, Senior Director, Oncology R&D, AstraZeneca
- Colette Johnston, Vice President - Head of Product Pipeline, Enara Bio
- Victoria Bentville, Principle Scientist, Scancell
- (Reserved) Ayako Pedersen, Vice President, Translational Research, IO Biotech
- (Reserved) Ben Thomas, Senior Vice President External Innovations & Operations, Oxford Biotherapeutics

NextGen Biomed 2026 Sponsors:


Gold Sponsors:



Silver Sponsors:



Bronze Sponsors:



Network & Programme Sponsors:



Immunotherapy & Immuno-Oncology Programme
Pre- Event Day – 23rd March 2026

12.30 – 13.00	Registration & Refreshments
	Cancer Vaccines & Personalised Cancer Therapies
13.00 – 13.25	Industry Presentation: Cancer Vaccines: A New Frontier In Therapy & Prevention
13.25 – 14.15	Panel Discussion: NextGen Vaccine Strategies To Advance Cancer Treatment <ul style="list-style-type: none"> • mRNA vaccine technology • AI analysis methods • Personalised vaccines
14.15- 14.40	Industry Presentation: Developing A Platform For Cancer Vaccine Development CONFIRMED: Victoria Brentville, Principal Scientist, Scancell
14.40 – 15.00	Refreshments
15.00 – 17.00	Sponsored Workshop For sponsorship opportunities please contact: sponsorship@oxfordglobal.com
17.00	End of Kick Off Day & Networking Drinks

Immunotherapy & Immuno-Oncology Programme
Day 1 – 24th March 2026

07.30 – 08.15	Registration		
08.15 – 08.25	Oxford Global's Welcome Address		
08.25 – 09.25	Opening Keynote Address & Fireside Chat with Keynote Speaker		
	Discovery & Development Of Therapies For Cancer & Autoimmune Diseases	Clinical Insights In Immuno-Oncology: Biomarkers, Pharmacokinetics & Safety Monitoring	Next-Gen Targets & Therapeutic Strategies: Identification, Validation & Emerging Platforms
09.25 – 09.50	Track Keynote Address: The Evolution Of TCR Bispecific In Solid Tumours CONFIRMED: Robert Wilkinson, Vice President, Research, Immunocore	Track Keynote Address: Patient selection & stratification for immuno-oncology	Track Keynote Address: Discovery Of Best-In-Class Therapeutic Antibodies In IO
09.50 – 10.15	Industry Presentation: Early Discovery Of CAR- T Therapies For Solid Tumours CONFIRMED: John Bridgeman, Chief Scientific Officer, Immuno Key	Industry Presentation: Title To Be Confirmed RESERVED: Annelise VuidePot, Senior Vice President, Chief Technology Officer, Research & UK Site Lead, Immunocore	Industry Presentation: Title To Be Confirmed RESERVED: Ben Thomas, Senior Vice President External Innovations & Operations, Oxford Biotherapeutics
10.15 – 10.40	Platinum & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Platinum & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Platinum & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com
10.40 – 11.40	Morning Break & Refreshments Poster Presentation Sessions 1-2-1 Meetings x3 Fireside Chats		
11.40 – 12.05	Gold & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Gold & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Gold & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com
12.05 – 12.30	Industry Presentation: AI-Driven Platform For TCR & Ab Therapeutics In Oncology And Autoimmunity CONFIRMED: Lilly Wollman, Chief Executive Officer, Synten	Panel Discussion: Cross Industry Collaboration For Clinical Success <ul style="list-style-type: none"> • Areas of collaboration • Ensuring clinical success through strategic partnerships 	Industry Presentation: Novel Targeting Strategies RESERVED: Colette Johnston, Vice President - Head of Product Pipeline, Enara Bio
12.55 – 13.20	Industry Presentation: Title To Be Confirmed RESERVED: Stefan Zielonka, Global Head of Antibody Discovery & Protein Engineering, Merck Healthcare KGaA		Industry Presentation: The Impact Of High Sensitivity High Throughput Screening In Oncology

Immunotherapy & Immuno-Oncology Programme
Day 1 – 24th March 2026

	Discovery & Development Of Therapies For Cancer & Autoimmune Diseases	Clinical Insights In Immuno-Oncology: Biomarkers, Pharmacokinetics & Safety Monitoring	Next-Gen Targets & Therapeutic Strategies: Identification, Validation & Emerging Platforms
13.20 – 14.20	<p style="text-align: center;">Lunch Poster Presentations Sessions 1-2-1 Meetings x3</p>		
14.20 – 15.10	<p>Thought Leadership Panel Discussion: Integrating AI Into The Development Of Immunotherapies</p> <ul style="list-style-type: none"> How is AI accelerating the identification of novel tumor antigens and neoantigens? Using AI to identify biomarkers that predict patient response to checkpoint inhibitors and other immunotherapies Optimizing clinical trial design <p><i>Reserved Panellist:</i> Lilly Wollman, Chief Executive Officer, Synteny</p>		
15.10 – 15.35	<p>Silver & Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>	<p>Silver & Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>	<p>Silver & Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>
15.35 – 16.35	<p style="text-align: center;">Afternoon Break Poster Presentations Sessions 1-2-1 Meetings x3 Fireside Chats</p>		
16.35 – 17.00	<p>Bronze & Above Solution Provider Presentation</p> <p style="text-align: center;">ATEM[®] STRUCTURAL DISCOVERY</p>	<p>Bronze & Above Solution Provider Presentation</p> <p style="text-align: center;">euROAPI</p>	<p>Bronze & Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>
17.00 – 17.25	<p>Panel Discussion: Applications Of T Cell Engagers In Immunotherapy</p> <ul style="list-style-type: none"> strategies to overcome T-cell exhaustion and antigen heterogeneity Approaches to make T-cell engagers work in solid tumors <p><i>Panellist:</i> Miguel Gaspar, Senior Director, Oncology R&D, AstraZeneca</p>	<p>Industry Presentation Development & Delivery Of Personalised Immunotherapy</p> <p>RESERVED: Livija Deban, Chief Scientific Officer, Prokarium</p>	<p>Panel Discussion: Successes & Challenges Of Technologies For Targeting Strategies</p> <ul style="list-style-type: none"> Benchmarking technologies across different therapeutic areas – oncology & autoimmune diseases Real-world examples of targeting strategies that succeeded or failed — and why
17.25 – 17.50	<p>Industry Presentation: Title To Be Confirmed</p> <p>CONFIRMED: James Legg, Chief Scientific Officer, Cytospire Therapeutics</p>	<p>Industry Presentation: New Biomarker Technologies In The Prediction Of Response</p>	




Immunotherapy & Immuno-Oncology Programme
Day 1 – 24th March 206

	Discovery & Development Of Therapies For Cancer & Autoimmune Diseases	Clinical Insights In Immuno-Oncology: Biomarkers, Pharmacokinetics & Safety Monitoring	Next-Gen Targets & Therapeutic Strategies: Identification, Validation & Emerging Platforms
17.50 – 18.15	Industry Presentation: Title To Be Confirmed CONFIRMED: Miguel Gaspar, Senior Director, Oncology R&D, AstraZeneca	Roundtable Discussion 1: Precision Strategies For Patient Stratification & Response Prediction <ul style="list-style-type: none"> Enhancing patient selection, stratification, and prediction of response using novel biomarker strategies and technologies Roundtable Discussion 2: Personalised Immunotherapy In Practice: Overcoming Clinical & Translational Barriers <ul style="list-style-type: none"> Tailoring immunotherapies based on individual tumor profiles and immune signatures 	Roundtable Discussion 1: What Makes A Target Clinically & Commercially Viable? <ul style="list-style-type: none"> 'Druggability' in immuno-oncology Early target validation strategies Roundtable Discussion 2: Tech-Enabled Target Discovery: Integrating Genomics, CRISPR & Computational Biology <ul style="list-style-type: none"> Role of single-cell genomics and spatial data in pinpointing actionable biology Promising targets discovered through novel computational tools & tech
18.20	Networking Drinks & Canapés Reception NextGen Biomed Networking Dinner		

Immunotherapy & Immuno-Oncology Programme
Day 2 – 25th March 2026

08.00 – 08.45	Closed-Door Invitation-Only Steering Research Meeting With Continental Breakfast		
09.00 – 09.25	Industry Keynote Address: Addressing Barriers To Participation In Immunotherapy Clinical Trials		
	Optimising Clinical Development: Efficacy, Safety & Combination Strategies	Multi-Omics Approaches In Immunotherapies	Translational Models In Immuno-Oncology: In Vitro & In Vivo Approaches
09.25 – 09.50	Track Keynote Address: Innovations In Imaging For Monitoring Tumour Dynamics And Immunotherapy Response In Real-Time	Track Keynote Address: Single Cell AI Applications For Immunotherapy Treatments For Cancer	Track Keynote Address: First In Class TS-Mrna Binder To Abolish Aberrant Protein Expression;Clinical Development Program CONFIRMED: Sonia Macia, Chief Medical Officer, Aromics Therapeutics
09.50 – 10.15	Industry Presentation: Non-Invasive Imaging To Assess Immune Cell Infiltration And Efficacy Of Combination Therapies	Industry Presentation: Unveiling Hidden Targets: AI-Driven Discovery Of Therapeutic Cancer Antigens From The Dark Genome	Industry Presentation: Recent Advances In Preclinical Immunogenicity Risk Assessment
10.15 – 10.40	Gold & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Gold & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Gold & Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com
10.40 – 11.40	Morning Coffee & Refreshments Poster Presentation Sessions 1-2-1 Meetings x3		
11.40 – 12.05	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com	Gold and Above Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com
12.05 – 12.35	Panel Discussion: Overcoming Efficacy Challenges In Oncology Drug Development <ul style="list-style-type: none"> Pre-clinical & translational considerations Clinical trial design & execution Technological & data-driven approaches 	Industry Presentation: Applications Of Multi-Omics Technologies In Immunotherapy	Industry Presentation: Choosing The Right Preclinical Models For Assessing Safety And Efficacy
12.35 – 13.00		Industry Presentation: Utilisation Of Spatial Technologies In Immuno- Oncology	Industry Presentation: The Role Of The Tumour Microenvironment In Ensuring Clinical Success
13.55 – 14.00	Lunch Poster Presentation Sessions 1-2-1 Meetings x3		

Immunotherapy & Immuno-Oncology Programme
Day 2 – 25th March 2026

	Optimising Clinical Development: Efficacy, Safety & Combination Strategies	Multi-Omics Approaches In Immunotherapies	Translational Models In Immuno-Oncology: In Vitro & In Vivo Approaches
14.00 – 14.25	<p>Solution Provider Presentation</p> <p></p>	<p>Silver and Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>	<p>Silver and Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>
14.25 – 14.50	<p>Bronze and Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>	<p>Solution Provider Presentation</p> <p></p>	<p>Solution Provider Presentation</p> <p></p>
14.50 – 15.15	<p>Industry Presentation: ctDNA As An Early Indicator Of Clinical Benefit From Tebentafusp In HLA-A*02:01 Positive Patients With Metastatic Uveal Melanoma</p>	<p>Industry Presentation: Nextgen & Single Cell Sequencing</p>	<p>Industry Presentation: Technologies To Transition From Animal Testing</p>
15.15 – 15.40	<p>Bronze and Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>	<p>Bronze and Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>	<p>Bronze and Above Solution Provider Presentation</p> <p>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</p>
15.40 – 16.00	<p>Afternoon Coffee & Refreshments</p> <p>Poster Presentation Sessions</p>		
16.00 – 16.25	<p>Industry Presentation: Navigating The Fluid Landscape Of Liquid Biopsy</p>	<p>Industry workshop: Real World Applications Of Spatial Technologies For The Development Of Immunotherapies</p> <ul style="list-style-type: none">Identifying novel immune targets with spatial omicsSpatial analysis in autoimmune diseasesIntegrating AI and spatial data for tumor modeling <p>Presentation 1:</p> <p>Presentation 2:</p> <p>Panel Discussion: Using Spatial Technology To Accelerate The Development Of The Next Generation Of Immunotherapies</p>	<p>Industry Workshop: Manipulating The Tumour Microenvironment Using Translational Models</p> <ul style="list-style-type: none">Humanised mouse models to enable precise manipulation of the TMEModeling & Manipulating angiogenesis in the TMEBridging gap between preclinical & clinical <p>Presentation 1:</p> <p>Presentation 2:</p> <p>Panel Discussion: Overcoming Challenges In Navigating The Tumour Microenvironment</p>
16.25 – 16.50	<p>Industry Presentation: Patient-Derived Microtumours In Preclinical Drug Development And Precision Oncology</p>		
16.50 – 17.15	<p>Industry Presentation: Connecting Bench To Bedside & Bedside To Bench: Example For Sym023 Asset, A Novel Anti-TIM3 Antibody, In Combination With Anti-PD1 In Solid Tumours</p>		
17.15 – 17.40	<p>Industry Presentation: Combination Strategies</p>		
17.40	<p>End of Programme</p>		